Viriom Inc.

May 04, 2020

Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients

Apr 08, 2020

Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19

Feb 17, 2020

Viriom to present results of Phase I study of the long acting injectable formulation of novel NNRTi for treatment of HIV-1 infection at CROI 2020

Sep 04, 2019

Viriom Wins Grant Award to Establish Affiliate in Mainland China

Sep 03, 2019

Viriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource Program

Jun 03, 2019

Viriom Files for Market Authorization in China

Feb 25, 2019

Viriom Announces New CEO Appointment

Dec 21, 2018

Viriom to Report Results from Phase 1b Clinical Trial of Once Weekly Oral HIV Treatment

Apr 16, 2018

Viriom to Present Pre-Clinical Studies with Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations at the International Conference on HIV/AIDS, STDs & STIs 2018

Dec 06, 2017

Viriom Announces New Director Appointment

Oct 03, 2017

Viriom will Present Latest Preclinical Data on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development at the 16th European AIDS Conference in Milano